A new analysis from the HEAR registry revealed that tafamidis is associated with significantly improved three-year survival in patients aged 80 and older with transthyretin cardiac amyloidosis (ATTR-CM). Hear from Dr. Hallie Blevins as she discusses this large real-world dataset and the importance of timely recognition and treatment of ATTR-CM in older patients—an often underrepresented group in clinical trials.
Podden och tillhörande omslagsbild på den här sidan tillhör
ReachMD. Innehållet i podden är skapat av ReachMD och inte av,
eller tillsammans med, Poddtoppen.
